Back to Search
Start Over
Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database
- Source :
- Drug Safety, Drug Safety, 36(6), 467-479. Adis, Drug Safety; Vol 36
- Publication Year :
- 2013
-
Abstract
- Background Drug-induced torsades de pointes (TdP) and related clinical entities represent a current regulatory and clinical burden. Objective As part of the FP7 ARITMO (Arrhythmogenic Potential of Drugs) project, we explored the publicly available US FDA Adverse Event Reporting System (FAERS) database to detect signals of torsadogenicity for antipsychotics (APs). Methods Four groups of events in decreasing order of drug-attributable risk were identified: (1) TdP, (2) QT-interval abnormalities, (3) ventricular fibrillation/tachycardia, and (4) sudden cardiac death. The reporting odds ratio (ROR) with 95 % confidence interval (CI) was calculated through a cumulative analysis from group 1 to 4. For groups 1+2, ROR was adjusted for age, gender, and concomitant drugs (e.g., antiarrhythmics) and stratified for AZCERT drugs, lists I and II (http://www.azcert.org, as of June 2011). A potential signal of torsadogenicity was defined if a drug met all the following criteria: (a) four or more cases in group 1+2; (b) significant ROR in group 1+2 that persists through the cumulative approach; (c) significant adjusted ROR for group 1+2 in the stratum without AZCERT drugs; (d) not included in AZCERT lists (as of June 2011). Results Over the 7-year period, 37 APs were reported in 4,794 cases of arrhythmia: 140 (group 1), 883 (group 2), 1,651 (group 3), and 2,120 (group 4). Based on our criteria, the following potential signals of torsadogenicity were found: amisulpride (25 cases; adjusted ROR in the stratum without AZCERT drugs = 43.94, 95 % CI 22.82–84.60), cyamemazine (11; 15.48, 6.87–34.91), and olanzapine (189; 7.74, 6.45–9.30). Conclusions This pharmacovigilance analysis on the FAERS found 3 potential signals of torsadogenicity for drugs previously unknown for this risk. Electronic supplementary material The online version of this article (doi:10.1007/s40264-013-0032-z) contains supplementary material, which is available to authorized users.
- Subjects :
- Male
Databases, Pharmaceutical
Torsadogenic Risk
spontaneous reporting
030204 cardiovascular system & hematology
Drug induced arrhythmia
Antipsychotics
Toxicology
Benzodiazepines
Adverse Event Reporting System
0302 clinical medicine
Phenothiazines
Torsades de Pointes
Tachycardia
Pharmacology (medical)
Original Research Article
030212 general & internal medicine
Death sudden cardiac
3. Good health
Olanzapine
Ventricular Fibrillation
Female
Medical emergency
Amisulpride
Antipsychotic Agents
Risk
medicine.medical_specialty
Pharmacology toxicology
Torsades de pointes
Cardiotoxins
03 medical and health sciences
mental disorders
Pharmacovigilance
medicine
Adverse Drug Reaction Reporting Systems
Humans
torsades de pointes
Signal detection
Intensive care medicine
Pharmacology
United States Food and Drug Administration
business.industry
nutritional and metabolic diseases
Arrhythmias, Cardiac
Cardiovascular Agents
medicine.disease
United States
nervous system diseases
Drug-induced arrhythmia
Death, Sudden, Cardiac
PHARMACOVIGILANCE
Cardiovascular agent
Sulpiride
business
Subjects
Details
- ISSN :
- 01145916
- Volume :
- 36
- Issue :
- 6
- Database :
- OpenAIRE
- Journal :
- Drug Safety
- Accession number :
- edsair.doi.dedup.....a4f9bd17b1886dff64ae384edd0c3b95
- Full Text :
- https://doi.org/10.1007/s40264-013-0032-z